Opinion: Rare disease treatment may not be a ‘real winner.’ But it’s definitely a miracle maker
Having a pharma industry titan take on your kid's ultra-rare disease was like having your big brother stand up to a schoolyard bully. Too bad it backed down.
by Maria Kefalas
Mar 08, 2018
4 minutes
When GlaxoSmithKline, long a global leader in the effort to pioneer gene replacement therapies, announced it would halt its drug development program for rare diseases, I understood that the decision made practical sense for the company. But as the mother of a child with a rare disease — one for which GSK was developing a highly effective treatment — I was devastated.
My daughter, Cal, was diagnosed with (MLD) at age 2. Within three months, she lost the ability to walk, talk, and eat. She uttered her final word — “Daddy” — five years ago. Now age 8, Cal is paralyzed, blind, and receives hospice care. We are grateful
You’re reading a preview, subscribe to read more.
Start your free 30 days